In the present study, we describe the generation and credentialing of an anti-CHFR antibody specifically generated for immunohistochemistry (IHC), then use this antibody to examine the relationship between CHFR expression and treatment outcome in newly diagnosed epithelial ovarian cancers treated with adjuvant platinum/taxane therapy and in ovarian cancer patient-derived xenografts (PDXs) treated with paclitaxel monotherapy. This evidence concerns the gene CHFR and ovarian carcinoma.